GlassScriptPhysician profile
Nina Blum
NPI 1922533256
$13,552.55
in general payments reported to CMS, 2019-2025
25 companies · $3,583 in 2025
The $3,583 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $291 · 2021: $626 · 2022: $1,949 · 2023: $2,959 · 2024: $4,145 · 2025: $3,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,686.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,910.16 | 2021-2025 | Enbrel, Krystexxa, Evenity |
| Ucb, INC. | $1,365.81 | 2022-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $1,161.06 | 2020-2025 | Rinvoq |
| Genzyme Corporation | $1,056.23 | 2022-2025 | |
| Janssen Biotech, INC. | $871.17 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $834.10 | 2022-2025 | |
| Lilly USA, LLC | $796.43 | 2021-2025 | Taltz, Zepbound, Olumiant |
| Pfizer INC. | $760.31 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $634.88 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Mallinckrodt Hospital Products INC. | $440.99 | 2022-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $431.13 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $416.90 | 2020-2025 | Orencia |
| Radius Health, INC. | $401.84 | 2022-2025 | Tymlos |
| Glaxosmithkline, LLC. | $373.75 | 2022-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $344.75 | 2022-2023 | Krystexxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.98 | 2023-2025 | Ofev, Cyltezo |
| Sobi, INC | $180.07 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $178.99 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $38.15 | 2022-2023 | Lupkynis |
| Genentech USA, INC. | $25.05 | 2025 | Actemra |
| Pacira Therapeutics, INC. | $23.70 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $22.18 | 2021 | |
| Fresenius Kabi USA, LLC | $16.68 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $15.87 | 2023 | Truxima |
| Sandoz INC. | $14.37 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Blum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.